Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Company Information
About this company
Key people
Paul Schwichtenberg
President, Chief Operating Officer
Mark L. Reisenauer
Chief Executive Officer, Director
Ajay Patel
Chief Financial Officer, Executive Vice President
Sam Schlessinger
Executive Vice President, General Counsel
Mary E Pietryga
Executive Vice President, Chief Commercial Officer
Heather L. Mason
Independent Chairman of the Board
Sravan K. Emany
Independent Director
Sigurd C. Kirk
Independent Director
William T. Mckee
Independent Director
David Matthew Stark
Independent Director
Click to see more
Key facts
- Shares in issue6.42m
- EPICASRT
- ISINUS04546C3043
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$66.32m
- Employees58
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.